» Articles » PMID: 3979015

Human Tamm-Horsfall Glycoprotein: Urinary and Plasma Levels in Normal Subjects and Patients with Renal Disease Determined by a Fully Validated Radioimmunoassay

Overview
Journal Clin Sci (Lond)
Date 1985 May 1
PMID 3979015
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

A recently developed, simple and sensitive radioimmunoassay has been used to examine 24 h excretion and plasma levels of Tamm-Horsfall glycoprotein (THG) in normal subjects, stone formers and patients with stable chronic renal disease. In normal subjects THG excretion ranged from 22 to 66 mg/24 h, with no sex difference and no correlation with creatinine clearance or body surface area. There was no correlation between 24 h THG excretion and urine volume, pH or osmolality, excretion of Na+, K+ or Ca2+ or free-water clearance. There was a small significant correlation between plasma THG concentration and urinary THG excretion. A good correlation was obtained between the THG/creatinine ratio in 24 h and random samples. This made possible the use of random samples to establish a reference range for THG excretion of 0.15-0.50 micrograms/ml of creatinine clearance which did not depend on sex or age. The excretion rate of THG in stone formers was generally within the reference range. It was not significantly different in those who were hypercalciuric or in those taking thiazides. In patients with chronic renal disease there was a good correlation between 24 h THG excretion, plasma THG concentration and creatinine clearance. The range of excretion of THG per ml of creatinine clearance was greater than in normal subjects, independent of the type of renal disease and unrelated to proteinuria. In patients with glomerulonephritis the excretion of THG per ml of creatinine clearance was significantly higher in those with well-preserved tubules compared with those with tubular atrophy.

Citing Articles

Relationship Between Serum Uromodulin as a Marker of Kidney Damage and Metabolic Status in Patients with Chronic Kidney Disease of Non-Diabetic Etiology.

Zeravica R, Ilincic B, Buric D, Jakovljevic A, Crnobrnja V, Ilic D Int J Mol Sci. 2024; 25(20).

PMID: 39456940 PMC: 11509006. DOI: 10.3390/ijms252011159.


Diagnosing Polyomavirus Nephropathy Without a Biopsy: Validation of the Urinary Polyomavirus-Haufen Test in a Proof-of-Concept Study Including Uromodulin Knockout Mice.

Nickeleit V, Butcher D, Thompson B, Rivier L, Singh H J Infect Dis. 2024; 230(5):1120-1129.

PMID: 38428993 PMC: 11566231. DOI: 10.1093/infdis/jiae107.


Uromodulin biology.

Karagiannidis A, Theodorakopoulou M, Pella E, Sarafidis P, Ortiz A Nephrol Dial Transplant. 2024; 39(7):1073-1087.

PMID: 38211973 PMC: 11210992. DOI: 10.1093/ndt/gfae008.


Urine Uromodulin, Kidney Tubulointerstitial Fibrosis, and Furosemide Response.

Bullen A, Vaingankar S, Madero M, Lopez Gil S, Macedo E, Ix J Nephron. 2023; 148(7):443-447.

PMID: 38043509 PMC: 11216347. DOI: 10.1159/000534578.


Unveiling the Hidden Power of Uromodulin: A Promising Potential Biomarker for Kidney Diseases.

Thielemans R, Speeckaert R, Delrue C, De Bruyne S, Oyaert M, Speeckaert M Diagnostics (Basel). 2023; 13(19).

PMID: 37835820 PMC: 10572911. DOI: 10.3390/diagnostics13193077.